

1. A pharmaceutical composition adapted for oral administration comprising 1 to 200mg of paroxetine methanesulfonate per unit dose, calculated on a free base basis, and a pharmaceutically acceptable carrier which comprises a disintegrant.

2. A composition according to claim 1 comprising 10 to 50mg of paroxetine methanesulfonate per unit dose, calculated on a free base basis.

3. A composition according to claim 1 or 2 comprising 10, 12.5, 15, 20, 25, 30 or 40mg of paroxetine methanesulfonate per unit dose, calculated on a free base basis.

4. A composition according to any one of claims 1 to 3 wherein the carrier comprises a binder.

5. A composition according to any one of claims 1 to 4 wherein the carrier comprises a colouring agent.

6. A composition according to any one of claims 1 to 5 wherein the carrier comprises a flavouring agent.

7. A composition according to any one of claims 1 to 6 wherein the carrier comprises a preservative.

8. A composition according to any one of claims 1 to 7 which is a tablet or capsule.

9. A process for the preparation of paroxetine methanesulfonate by precipitation (including crystallization or re-crystallization) from a solution of a paroxetine methanesulfonate, or spray drying or freeze drying a solution of a paroxetine methanesulfonate, wherein the solution of paroxetine methanesulfonate, comprises a solvent which is toluene, an alcohol, an ester, a ketone, a halogenated hydrocarbon, a nitrile, or an ether, optionally in admixture with water, an ether, or

a lower alcohol, or mixtures thereof, with the proviso that the solvent for precipitation is not ethyl acetate.

10. A process according to claim 9 wherein the solvent forms an azeotrope with water and prior to isolation of the product water is removed by azeotropic distillation.

11. A process according to claim 9 or 10 in which the crystallization is promoted by inclusion of an anti-solvent to the solvent, in which the anti-solvent is an ether or hexane.

12. A process according to any one of claims 9 to 11 in which the crystallization is conducted at elevated temperature followed by controlled cooling.

13. A process according to any one of claims 9 to 12 in which the crystallization is induced by the addition of a seed crystal.

14. A process according to any one of claims 9 to 13 in which the crystallization is conducted without a seed crystal.

15. Use of paroxetine methanesulfonate in the preparation of a medicament for use in the treatment and/or prevention of any one or more of the disorders selected from alcoholism, trichotillomania, substance abuse, anxiety, chronic pain, adolescent depression and dysthymia.

16. A pharmaceutical composition comprising 10mg of paroxetine methanesulfonate per unit dose, calculated on a free base basis, and a pharmaceutically acceptable carrier.

17. A pharmaceutical composition comprising 12.5mg of paroxetine methanesulfonate per unit dose, calculated on a free base basis, and a pharmaceutically acceptable carrier.

18. A pharmaceutical composition comprising 15mg of paroxetine methanesulfonate per unit dose, calculated on a free base basis, and a pharmaceutically acceptable carrier.

19. A pharmaceutical composition comprising 20mg of paroxetine methanesulfonate per unit dose, calculated on a free base basis, and a pharmaceutically acceptable carrier.

20. A pharmaceutical composition comprising 25mg of paroxetine methanesulfonate per unit dose, calculated on a free base basis, and a pharmaceutically acceptable carrier.

21. A pharmaceutical composition comprising 30mg of paroxetine methanesulfonate per unit dose, calculated on a free base basis, and a pharmaceutically acceptable carrier.

22. A pharmaceutical composition comprising 40mg of paroxetine methanesulfonate per unit dose, calculated on a free base basis, and a pharmaceutically acceptable carrier.

23. A pharmaceutical composition according to any one of claims 16 to 22 which is a tablet or capsule.

24. A pharmaceutical composition comprising 1 to 200mg of paroxetine methanesulfonate per unit dose, calculated on a free base basis, and a pharmaceutically acceptable carrier.